Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
Alessandra DamassiMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy.ORCID 0000-0001-5052-0870
Malvina CremanteMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy.ORCID 0000-0002-4778-0038
Alessio SignoriDepartment of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, 16132, Italy.ORCID 0000-0001-6289-9144
Sara Elena RebuzziMedical Oncology Unit, Ospedale San Paolo, Savona, 17100, Italy.ORCID 0000-0003-0546-6304
Andrea MalgeriDepartment of Medical Oncology, Università Campus Biomedico of Roma, Rome, 00128, Italy.ORCID 0009-0008-6430-7235
Marilena Di NapoliDepartment of Urology & Gynecology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Napoli, 80131, Italy.ORCID 0000-0003-4516-7341
Giandomenico RovielloDepartment of Health Sciences, Section of Clinical Pharmacology & Oncology, University of Firenze, Firenze, 50139, Italy.ORCID 0000-0001-5504-8237
Veronica PratiDepartment of Medical Oncology, Ospedale Michele e Pietro Ferrero, Verduno-Azienda Sanitaria Locale CN2, Verduno, 12060, Italy.
Marianna TudiniMedical Oncology, St. Salvatore Hospital, L'Aquila, 67100, Italy.
Francesco AtzoriSSD Oncologia Medica, Ospedale Sirai di Carbonia, ASL Sulcis, 09013, Italy.ORCID 0000-0002-8211-0363
Marco MessinaMedical Oncology, Ospedale Civico (A.R.N.A.S.), Palermo, 90127, Italy.
Franco MorelliOncology department, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013, Italy.ORCID 0000-0003-2378-9094
Giuseppe PratiDepartment of Oncology & Advances Technologies, IRCCS - AUSL Reggio Emilia, Guastalla, 41016, Italy.ORCID 0000-0003-4434-6807
Franco NolèMedical Oncology Division of Urogenital & Head & Neck Tumors, IEO, European Institute of Oncology IRCCS, Milan, 20141, Italy.ORCID 0000-0002-4326-7544
Fabio CatalanoMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy.ORCID 0000-0001-5002-9782
Veronica MurianniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy.ORCID 0000-0002-4955-0295
Pasquale RescignoTranslational & Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, NE7 7DN, United Kingdom.ORCID 0000-0002-4668-4765
Giuseppe Luigi BannaPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, United Kingdom.ORCID 0000-0003-0764-3650
Giuseppe FornariniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy.ORCID 0000-0003-4754-6572
Sebastiano ButiMedical Oncology Unit, University Hospital of Parma, Parma, 43126, Italy.ORCID 0000-0003-0876-0226
Funding
Italian Ministry of Health Ricerca Corrente 2018-2021 grants
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. · full record | OpenQuestion